Health Affairs September 4, 2019
Cell and gene therapies have the potential to revolutionize treatment for a range of severe diseases, but their introductions also force difficult economic conversations. This blog post offers three observations to help the community evaluate the costs and benefits of new—and in many cases, extremely costly—therapies.
Expensive Cell And Gene Therapies May Fare Well In Cost-Effectiveness Analyses
Expensive therapies—even those with record high prices—may offer substantial health gains and thus have comparable value, in terms of cost-effectiveness, to less expensive conventional treatments. To assess the extent to which cell and gene therapies offer true breakthrough health benefits, we compared the incremental quality-adjusted life year (QALY) gains associated with cell and gene therapies to corresponding gains for conventional (small molecule)...
Today's Sponsors
Today's Sponsor